MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

Official title

Focal Prostate Ablation for Low to Intermediate Grade Cancer Utilizing TULSA Profound System

Overview

This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer. MRI-guided TULSA ablation is a minimally invasive procedure that uses an ultrasound device guided by MRI imaging to deliver high-energy sound waves, producing very high temperature to ablate (destroy) tumor cells in a targeted manner. The MRI-guided TULSA procedure may help patients avoid surgery and help improve prostate cancer patients' quality of life.

Detailed description

PRIMARY OBJECTIVE:

I. To perform the TULSA procedure for safety and efficacy outcomes in men aged 45 to 80 years with biopsy-confirmed, National Comprehensive Cancer Network (NCCN) low to intermediate-risk prostate cancer.

SECONDARY OBJECTIVE:

I. To assess patient-reported metrics for quality of life (QOL). II. To assess return to normal activity. III. Compare economic benefit as noted from Expanded Prostate Cancer Index Composite (EPIC) questionnaire.

OUTLINE:

Patients undergo MRI-guided TULSA. Patients may also undergo digital rectal exam (DRE), cystoscopy, biopsy, bone scan, prostate specific membrane antigen (PSMA) positron emission tomography (PET), and/or multiparametric MRI (mpMRI) at screening.

After completion of study treatment, patients are followed at 3, 6, 9, 12, 15, 18, 21 and 24 months.

Interventions

• Procedure MRI-Guided Transurethral Ultrasound Ablation
  Undergo MRI-Guided TULSA
• Other Questionnaire Administration
  Ancillary studies
• Procedure Digital Rectal Examination
  Undergo DRE
• Procedure Cystoscopy
  Undergo cystoscopy
• Procedure Biopsy
  Undergo biopsy
• Procedure Bone Scan
  Undergo bone scan
• Procedure PSMA PET Scan
  Undergo PSMA PET
• Procedure Multiparametric Magnetic Resonance Imaging
  Undergo mpMRI

Primary outcome measures

• Proportion of patients free from treatment failure [Time frame: At 24 months post-treatment]
• Proportion of patients who maintain both urinary continence and erectile potency [Time frame: At 12 months]

Secondary outcome measures (12)

• Biochemical failure [Time frame: Up to 24 months]
• Histologic failure [Time frame: At 12 months]
• Multiparametric magnetic resonance imaging (mpMRI) Prostate Imaging and Reporting and Data System (PI-RADS) version 2 score for each visible lesion [Time frame: At 24 months post-treatment]
• Total prostate volume [Time frame: At 24 months post-treatment]
• Salvage-free survival [Time frame: Up to 24 months]
• Biochemical failure-free survival [Time frame: Up to 24 months]
• Histologic failure-free survival [Time frame: Up to 24 months]
• Metastasis-free survival [Time frame: Up to 24 months]
• Prostate cancer-specific survival [Time frame: Up to 24 months]
• Overall survival [Time frame: Up to 24 months]
• Change in quality of life [Time frame: Baseline up to 24 months]
• Change in patient-reported genitourinary function [Time frame: Baseline up to 24 months]

Eligibility criteria

Inclusion criteria

• Male
• Age 45-80 years, with > 10 years life expectancy
• Biopsy-confirmed, NCCN \[Gleason Grade (GG) 1, favorable GG 2 and unfavorable GG3\] intermediate-risk prostate cancer
• Stage =< T2c, N0, M0
• International Society of Urological Pathology (ISUP) grade group 1, 2, or 3 disease on transrectal ultrasonography (TRUS)-guided biopsy (minimum 8 cores, combination of systematic and MRI fusion-guided) or in-bore biopsy \[minimum 3 cores from each Prostate Imaging-Reporting and Data System (PI-RADS) version (v)2 category >= 3 lesion\]. Biopsy reported within 12 months of baseline visit, with minimum 6-week interval between biopsy and baseline
• Prostate specific antigen (PSA) =< 20 ng/mL reported within 3 months of baseline
• Treatment naive
• Planned ablation volume < 3.0 cm axial radius from the urethra on mpMRI acquired within 6 months of baseline

Exclusion criteria

• Inability to undergo MRI or general anaesthesia
• Suspected tumour > 30 mm from the prostatic urethra or < 14 mm from the prostatic urethra
• Prostate calcifications > 3 mm in maximum extent obstructing ablation of tumor on low-dose pelvic computed tomography (CT)

• Criteria subject to additional review and approval by sponsor. Alternatively, prospective TRUS to query calcifications or susceptibility-weighted MRI if available may be used to assess calcification. Imaging for calcification screening must be dated within 1 year of baseline visit
• Unresolved urinary tract infection or prostatitis
• History of proctitis, bladder stones, hematuria, history of acute urinary retention, severe neurogenic bladder
• Artificial urinary sphincter, penile implant or intraprostatic implant
• Less than 10 years life expectancy
• Patients who are otherwise not deemed candidates for radical prostatectomy (RP)
• Inability or unwillingness to provide informed consent
• History of anal or rectal fibrosis or stenosis, or urethral stenosis, or other abnormality challenging insertion of devices

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT05438563 · 22-001336

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗